Safety of Low Volume Iodinated Contrast Administration for Arteriovenous Fistula Intervention in Chronic Kidney Disease Stage 4 or 5 Utilizing a Bicarbonate Prophylaxis Strategy

Seminars in Dialysis

Volumn 23, Issue 6, 2010, Pages 638-642

  Eisenhart, Elizabeth ^a   Benson, Scott ^a   Lacombe, Patricia ^a   Himmelfarb, Jonathan ^b   Zimmerman, Robert ^a   Schimelman, Brad ^a   Parker, Mark G ^a  

^a MAINE MEDICAL CENTER   (United States)

^b Kidney Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CONTRAST MEDIUM; IODOBENZOIC ACID DERIVATIVE; IOVERSOL;

ACUTE KIDNEY FAILURE; AGED; ARTERIOVENOUS SHUNT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RADIOGRAPHY; RENAL REPLACEMENT THERAPY; URINE;

ACUTE KIDNEY INJURY; AGED; ARTERIOVENOUS SHUNT, SURGICAL; BICARBONATES; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; TRIIODOBENZOIC ACIDS;

EID: 78650343101     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00800.x     Document Type: Article

References (37)

1. National Kidney Foundation Vascular Access 2006 Workgroup: Clinical practice guidelines for vascular access. Am J Kidney Dis 48(Suppl 1):S176-S247, 2006
2. Besarab A, Brouwer D: Improving arteriovenous fistula construction: fistula first initiative. Hemodial Int 8:199-206, 2004
3. Miller CD, Robbin ML, Allon M: Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. Kidney Int 63:346-352, 2003
4. Miller PE, Tolwani A, Luscy CP, Deierhoi MH, Bailey R, Redden DT, Allon M: Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int 56:275-280, 1999
5. Rayner HC, Pisoni RL, Gillespie BW, Goodkin DA, Akiba T, Akizawa T, Saito A, Young EW, Port FK: Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 63:323-330, 2003
6. Beathard GA: An algorithm for the physical examination of early fistula failure. Semin Dial 18:331-335, 2005
7. Beathard GA, Arnold P, Jackson J, Litchfield T: Aggressive treatment of early fistula failure. Kidney Int 64:1487-1494, 2003
8. Beathard GA, Settle SM, Shields MW: Salvage of the nonfunctioning arteriovenous fistula. Am J Kidney Dis 33:910-916, 1999
9. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J: Risk prediction of contrast-induced nephropathy. Am J Cardiol 98:27K-36K, 2006
10. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103:368-375, 1997
11. McCullough PA: Acute kidney injury with iodinated contrast. Crit Care Med 36:S204-S211, 2008
12. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 95:13-19, 2005
13. Geoffroy O, Tassart M, Le Blanche AF, Khalil A, Duedal V, Rossert J, Bigot JM, Boudghene FP: Upper extremity digital subtraction venography with gadoterate meglumine before fistula creation for hemodialysis. Kidney Int 59:1491-1497, 2001
14. Rieger J, Sitter T, Toepfer M, Linsenmaier U, Pfeifer KJ, Schiffl H: Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 17:824-828, 2002
15. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362, 2006
16. Perazella MA, Rodby RA: Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 20:179-185, 2007
17. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton III CA, Rittase RA, Norton HJ, Kennedy TP: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291:2328-2334, 2004
18. Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, Patel A, Vasheghani-Farahani A, Sadigh G, Perkovic V: Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 151:631-638, 2009
19. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A: Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115:1211-1217, 2007
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999
21. Vascular Access, United States Renal Data System, accessed November 5 2010
22. Allon M, Robbin ML: Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 62:1109-1124, 2002
23. Allon M: Current management of vascular access. Clin J Am Soc Nephrol 2:786-800, 2007
24. Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 89:615-620, 1990
25. Asif A, Cherla G, Merrill D, Cipleu CD, Tawakol JB, Epstein DL, Lenz O: Venous mapping using venography and the risk of radiocontrast-induced nephropathy. Semin Dial 18:239-242, 2005
26. Kian K, Wyatt C, Schon D, Packer J, Vassalotti J, Mishler R: Safety of low-dose radiocontrast for interventional AV fistula salvage in stage 4 chronic kidney disease patients. Kidney Int 69:1444-1449, 2006
27. Pannu N, Wiebe N, Tonelli M: Prophylaxis strategies for contrast-induced nephropathy. JAMA 295:2765-2779, 2006
28. Briguori C, Colombo A, Airoldi F, Morici N, Sangiorgi GM, Violante A, Focaccio A, Montorfano M, Carlino M, Condorelli G, Ricciardelli B: Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 68:2250-2255, 2005
29. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A: Early detection of acute renal failure by serum cystatin C. Kidney Int 66:1115-1122, 2004
30. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 54:1012-1024, 2009
31. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S: Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 26:287-292, 2006
32. Hirsch R, Dent C, Pfriem H, Allen J, Beekman III RH, Ma Q, Dastrala S, Bennett M, Mitsnefes M, Devarajan P: NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 22:2089-2095, 2007
33. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Pawlak K, Mysliwiec M, Lawnicki S, Szmitkowski M, Dobrzycki S: Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values? Kidney Blood Press Res 30:408-415, 2007
34. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Poniatowski B, Pawlak K, Dobrzycki S: NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol 127:290-291, 2008
35. Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D, Jiaqi Q: Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 108:c176-c181, 2008
36. Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Malyszko JS, Dobrzycki S: Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail 31:910-919, 2009
37. Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S: NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Adv Med Sci 54:221-224, 2009